Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II/III Clinical Trial on the Efficacy and Safety of Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune-related Pneumonia
Conditions
Interventions
Pirfenidone Capsules （400 mg）
Pirfenidone Capsules（600mg）
+1 more
Locations
36
China
Anhui Provincial Chest Hospital
Hefei, Anhui, China
Chinese Academy of Medical Sciences Cancer Hospital
Beijing, Beijing Municipality, China
Affiliated Hospital of Fujian Medical University, Xiehe Branch
Fuzhou, Fujian, China
Fujian Provincial Cancer Hospital
Fuzhou, Fujian, China
Lanzhou University First Hospital
Lanzhou, Gansu, China
Foshan First Hospital
Foshan, Guangdong, China
Start Date
March 26, 2026
Primary Completion Date
December 30, 2026
Completion Date
December 30, 2026
Last Updated
April 22, 2026
Lead Sponsor
Beijing Continent Pharmaceutical Co, Ltd.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions